RECURRENT PROSTATE CARCINOMA

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard radiation therapy alone versus radiation plus a drug called apalutamide, which blocks male hormones that fuel cancer growth. The goal is to see if the combination d…

This study looks at men whose prostate cancer has returned after surgery or radiation. It compares standard hormone therapy (which lowers testosterone) to the same therapy plus abiraterone and prednisone, which further block testosterone production. The goal is to see if the comb…

This study tests whether combining surgery and radiation can help men whose prostate cancer has returned and spread to a few spots in the body. Twenty participants will receive targeted treatments to remove or destroy these cancer spots. The main goal is to see if this approach c…

This study looks at men whose prostate cancer has returned after initial treatment, shown by rising PSA levels. It tests whether adding an experimental drug (MK-2206) to the standard hormone therapy bicalutamide works better than bicalutamide alone. The goal is to see if the comb…

This study tests whether white button mushroom supplements can lower PSA levels in men with prostate cancer that has returned or is low-risk and not yet treated. About 133 participants take the supplement or follow standard monitoring. The goal is to see if the mushrooms affect P…

This study tests whether adding the immunotherapy drug pembrolizumab can help men with advanced prostate cancer that has stopped responding to the hormone therapy enzalutamide. About 58 men whose cancer continued to grow despite enzalutamide will receive pembrolizumab. The main g…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA …

This study is testing a two-part treatment for men whose prostate cancer has returned and spread to a few other places in the body. The treatment combines hormone-blocking drugs with very precise, high-dose radiation aimed directly at the cancer spots. The goal is to see if this …

This study is testing whether a shorter, more intense course of radiation has fewer side effects for men whose prostate cancer has returned and spread to a few lymph nodes. It compares two radiation methods: proton beam therapy and standard IMRT. The main goal is to see which app…

This study tests whether adding furosemide (a diuretic or "water pill") to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels rose after prostate removal. Participants receive two scans—one with and…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study looks at how certain hormone therapies for advanced prostate cancer might affect thinking skills like memory and attention. About 100 men who are already on these treatments will take thinking tests and have brain scans to see if there are changes. The goal is to under…

This study is for men with prostate cancer that has spread and is no longer responding to hormone therapy. Researchers collect tissue, blood, and urine samples to study gene changes and look for biomarkers. The goal is to better understand how the cancer behaves and how patients …